IP Library Granted Patent US 9,040,531
Granted Patent B2
US 9,040,531 · App. 13/319,071 · Granted May 26, 2015

Alpha helix mimetics and methods relating thereto

Inventors: Takenao Odagami (Yokohama, JP); Yuji Kogami (Yokohama, JP); Hiroyuki Kouji (Yokohama, JP)
Assignee: PRISM BioLab Co., Ltd.
C07D487/04C07D401/14C07D403/14C07D495/14C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,040,531
App. No.
13/319,071
Granted
May 26, 2015
Kind
B2
Abstract

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

Claims (88)

1. A compound having the following general formula (I):

wherein

is single bond or double bond;

A is —CHR 7 —,

wherein

R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3;

G and Y are independently carbon atom or nitrogen atom;

R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R 2 is —W 21 —W 22 —Rb—R 20 ,

wherein

W 21 is —(CO)—or —(SO 2 )—,

W 22 is bond, —O—, —NH— or optionally substituted lower alkylene,

Rb is bond or optionally substituted alkylene, and

R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;

with the proviso that

when B is benzene, and R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 ,

wherein

R 3 is hydrogen or optionally substituted alkyl.

3. The compound of claim 1 , which has the following general formula (I-d):

wherein

is single bond or double bond;

A is —(CHR)—;

wherein

R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3;

G is carbon atom or nitrogen atom;

R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R 2 is —W 21 —W 22 —Rb—R 20 ,

wherein

W 21 is —(CO)—or —(SO 2 )—,

W 22 is bond, —O—, —NH— or optionally substituted lower alkylene,

Rb is bond or optionally substituted lower alkylene, and

R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;

with the proviso that

when B is benzene, and R 2 is —W 21 —W 22 —Rb 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl.

4. The compound of claim 1 ,

wherein

B is optionally substituted 5-membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y.

5. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

6. A compound having the following general formula (II):

wherein

is single bond or double bond;

A is —CHR 7 —,

wherein

R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3;

G and Y are independently carbon atom or nitrogen atom;

R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R 2 is —W 21 —W 22 —Rb—R 20 ,

wherein

W 21 is —(CO)—or —(SO 2 )—,

W 22 is bond, —O—, —NH—or optionally substituted lower alkylene,

Rb is bond or optionally substituted alkylene, and

R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;

R 91 is selected from optionally substituted alkyl, linker and solid support; and

R 92 is selected from optionally substituted alkyl, linker and solid support;

with the proviso that

when B is benzene, and R 21 is W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl;

or a salt thereof.

7. A process for preparing a compound having the following general formula (I):

wherein

is single bond or double bond;

A is —CHR 7 —,

wherein

R 7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

B is optionally substituted 3-, 4-, 5-, 6- or 7- membered saturated or unsaturated monocyclic carbocyclic ring formed together with G and Y, or is optionally substituted 4-, 5-, 6- or 7 membered saturated or unsaturated heterocyclic ring formed together with G and Y and the hetero atom is selected from S, N and O and the number of hetero atoms is an integer of 1-3;

G and Y are independently carbon atom or nitrogen atom;

R 1 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;

R 2 is —W 21 —W 22 —Rb—R 20 ,

wherein

W 21 is —(CO)—or —(SO 2 )—,

W 22 is bond, —O—, —NH— or optionally substituted lower alkylene,

Rb is bond or optionally substituted alkylene, and

R 20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl; and

R 3 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;

with the proviso that

when B is benzene, and R 2 is —W 21 —W 22 —Rb—R 20 , wherein W 21 is —(CO)—, W 22 is —NH—, and Rb is bond, then R 20 should not be optionally substituted phenyl;

or a salt thereof, which comprises reacting a compound having the following general formula (II):

wherein

R 91 is selected from optionally substituted alkyl, linker and solid support;

R 92 is selected from optionally substituted alkyl, linker and solid support; and

the other symbols are as defined above, or a salt thereof, with an acid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2014
From: PRISM PHARMA CO., LTD.
To: PRISM BIOLAB CO., LTD.
Reel/Frame 033596/0182 →
CHANGE OF NAME Recorded Aug 19, 2014
From: PRISM BIOLAB CORPORATION
To: PRISM PHARMA CO., LTD.
Reel/Frame 033568/0279 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2011
From: ODAGAMI, TAKENAO; KOGAMI, YUJI; KOUJI, HIROYUKI
To: PRISM BIOLAB CORPORATION
Reel/Frame 027454/0160 →
Continuity (3)
Provisional Application 61176348 · May 7, 2009
Provisional Application 61176363 · May 7, 2009
Related Publication 20120088770A1 · Apr 12, 2012